Table 2.

Multivariable repeated measures analysis of potential risk factors of trends in eGFR for 821 patients

VariableParameter Estimate95% Confidence IntervalP Value
Intercept92.3682.3 to 102.4<0.001
Time, yra (coded as 0–13, continuous)−0.73−0.87 to −0.59<0.001
Sex
 Women−2.50−4.58 to −0.430.02
 Men (reference)
Ethnicity
 Asian versus white4.540.58 to 8.490.03
 Black versus white7.843.74 to 11.950.002
 Unknown/other versus white0.54−6.40 to 7.480.88
 White (reference)
Age at first cisplatin−0.51−0.59 to −0.440.001
Cisplatin dose (mg/m2)
 101–250 versus >70111.101.65 to 20.550.02
 251–400 versus >7016.93−2.61 to 16.460.16
 401–550 versus >7015.52−4.24 to 15.270.23
 551–700 versus >7016.51−5.27 to 18.280.28
 ≤100 versus >7019.58−0.50 to 19.660.06
 >701 (reference)
  • Model was fit using a compound symmetry covariance structure.

  • a Time 0 is baseline; time 1 is last cisplatin date; time 2 is year 1 after cisplatin, and so on until time 13, which is year 12 after cisplatin.